Previous Article | Next Article 
Journal of Virology, August 2001, p. 6857-6864, Vol. 75, No. 15
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.15.6857-6864.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
Identification of a Conserved Residue of Foamy
Virus Gag Required for Intracellular Capsid Assembly
Scott W.
Eastman and
Maxine
L.
Linial*
Division of Basic Sciences, Fred Hutchinson
Cancer Research Center, Seattle, Washington 98109, and Department
of Microbiology, University of Washington, Seattle, Washington 98195
Received 27 December 2000/Accepted 3 May 2001
 |
ABSTRACT |
In contrast to all retroviruses but similar to the hepatitis B
virus, foamy viruses (FV) require expression of the envelope protein
for budding of intracellular capsids from the cell, suggesting a
specific interaction between the Gag and Env proteins. Capsid assembly
occurs in the cytoplasm of infected cells in a manner similar to that
for the B- and D-type viruses; however, in contrast to these
retroviruses, FV Gag lacks an N-terminal myristylation signal and
capsids are not targeted to the plasma membrane (PM). We have found
that mutation of an absolutely conserved arginine (Arg) residue at
position 50 to alanine (R50A) of the simian foamy virus SFV cpz(hu)
inhibits proper capsid assembly and abolishes viral budding even in the
presence of the envelope (Env) glycoproteins. Particle assembly and
extracellular release of virus can be restored to this mutant with the
addition of an N-terminal Src myristylation signal (Myr-R50A),
presumably by providing an alternate site for assembly to occur at the
PM. In addition, the strict requirement of Env expression for capsid
budding can be bypassed by addition of a PM-targeting signal to Gag.
These results suggest that intracellular capsid assembly may be
mediated by a signal akin to the cytoplasmic targeting and retention
signal CTRS found in Mason-Pfizer monkey virus and that FV Gag has the
inherent ability to assemble capsids at multiple sites like
conventional retroviruses. The necessity of Env expression for particle
egress is most probably due to the lack of a membrane-targeting signal
within FV Gag to direct capsids to the PM for release and indicates
that Gag-Env interactions are essential to drive particle budding.
 |
INTRODUCTION |
Foamy viruses (FV), classified in
the Spumavirus genus of the Retroviridae family,
are unique viruses sharing morphogenic features found among many
diverse types of enveloped viruses, including the human hepatitis B
virus. Although FVs cause substantial cytopathic effects in tissue
culture (hence the name "foamy", referring to the highly vacuolated
appearance of infected cells), an asymptomatic and persistent infection
is seen in nature in a wide variety of organisms including nonhuman
primates, cats, cattle, and horses (22, 27, 42, 46). The
genomic organization of the FVs, including the prototype molecular
cloned simian foamy virus SFVcpz(hu), is similar to that of other
complex retroviruses, with several additional open reading frames
located 3' of the canonical gag, pol, and env
genes, including the transcriptional transactivator gene,
tas (23, 29, 36). Unlike in retroviruses, however, the Pol protein is expressed from a unique spliced mRNA, not as a Gag-Pol fusion, and therefore must be specifically
incorporated into newly forming capsids (14, 28, 47). In
addition, reverse transcription of the genome is initiated early,
during budding of capsids, viral egress, or prior to infection of new
cells, suggesting a novel coordination of morphogenesis
(50).
The main FV structural protein, Gag, is also different from that of
other retroviruses because of the lack of proteolytic processing into
the MA, CA, and NC domains, and, correspondingly, extracellular viral
particles possess an immature morphology (9). The majority
of viral protease-specific Gag cleavage is limited to a single event
near the C terminus of the protein, releasing an approximately 3-kDa
protein from the 71-kDa precursor peptide (13, 16, 35),
although it has been proposed that additional cleavage occurs on
infection of new cells during viral uncoating (16, 34,
39). In addition, FV Gag lacks the major homology region found
in the capsid proteins of all other retroviruses, as well as the
signature Cys-His box motifs found in all retroviral Gag NC proteins
(43a). Instead, FV Gag possesses three glycine-arginine rich domains, termed GR boxes I to III, situated at the C terminus of
the protein, which are involved in nucleic acid binding and nuclear
localization (41, 48) and possibly particle density (4). By 24 h postinfection, a strong nuclear Gag
signal is seen in all cell types infected with FVs (the serological
hallmark of FV infection), although transport of Gag to the nucleus is not essential for the production of infectious virus and the role of
Gag nuclear localization is not known (22, 41, 48).
FV particle assembly occurs in the cytosolic compartment (8,
10). Similar to the intracisternal A-type particles but distinct
from all other retroviruses, FV capsids bud through the endoplasmic
reticulum (ER) membrane. The FV envelope (Env) protein is also retained
in the ER by means of a trilysine motif located at the C-terminal
cytoplasmic tail of Env (18, 19). FV morphogenesis requires the presence of the Env protein to allow release of virus from
the cell, a mechanism also employed by hepatitis B virus, such that
capsid budding is completely inhibited in the absence of Env expression
(2, 5, 15). In contrast, all other retroviruses have the
ability to assemble and bud capsids from a variety of cell types on the
sole expression of the gag gene (3; Wills and
Craven, Editorial).
While the mechanism of intracellular capsid assembly is not fully
understood for the B- and D-type retroviruses, recent experiments with
the D-type retrovirus Mason-Pfizer monkey virus (MPMV) have show that
an 18-amino-acid domain near the N terminus of Gag, termed the
cytoplasmic targeting and retention signal (CTRS) and centered on a
highly conserved arginine (Arg) residue at position 55, is required to
direct the cytoplasmic assembly of capsids (7, 32, 38,
40). Mutation of Arg55 of Gag to tryptophan (R55W) results in a
switch of morphology to the default type C capsid assembly at the
plasma membrane (PM), a process dependent on the N-terminal
myristylation signal (37, 38). Remarkably, fusion of the
CTRS to green fluorescent protein (GFP) resulted in discrete staining
at cytoplasmic sites, and, furthermore, addition of the CTRS to the
C-type retrovirus Moloney murine leukemia virus Gag protein conferred
intracellular assembly (7).
All sequenced FV Gag proteins have a high level of conservation near
the N terminus, including an absolutely conserved arginine at amino
acid 50. Comparison of this region of FV Gag with the CTRS of MPMV
reveals a number of identical residues, comprising a domain of FV Gag
[GXWGX3RX7L(Q/V)D], centered
on the conserved Arg (7, 42). We predicted that if
cytoplasmic assembly of FV capsids is mediated by sequences in
this region, mutation of conserved residues might block assembly
altogether, since the FV Gag protein is not myristylated and is not
known to possess a membrane-targeting signal. We found that alanine or
tryptophan substitution at position 50 (R50A/W) of SFVcpz(hu) severely
disrupts capsid assembly in transfected cells and completely abolishes the release of virus from the cell even in the presence of Env. Capsid
assembly and budding of the R50A mutant was restored if Gag was given a
targeting signal via the addition of an N-terminal Src myristylation
signal (33, 43, 44). Extracellular particles were produced
at wild-type levels but were not infectious, and Gag cleavage was
completely blocked. Surprisingly, addition of a myristylation signal
bypassed the strict requirement for Env in particle budding, suggesting
that Gag does not possess an inherent targeting signal and therefore
relies on interaction with Env for particle egress.
 |
MATERIALS AND METHODS |
Recombinant plasmid DNAs.
The infectious molecular clone of
SFVcpz(hu), designated pHSRV13, was used for all experiments described
below (30). Proviral mutants R50A and R50W were created by
PCR mutagenesis using the Morph kit (5 Prime
3 Prime) with a modified
version of FV subclone 1 (2) renamed G3 (AvrII
and EcoRV sites deleted from the polylinker, consisting of a
2,885-bp fragment of pHSRV13 from EagI to SwaI) as a template and using the oligonucleotides primers MAR1A
(5'-GGACAAATT GAGGCATTTCAGATGG-3') and MAR1W
(5'-GTGGGGACAAATTGAGTGGTTTC AGATGGTACG-3') to change
the Arg residue (AGA) to Ala (GCA) and Trp (TGG), respectively. The Src
myristylation signal (GSSKSKPKD) was introduced into the G3
subclone by inverse PCR with the oligonucleotides SRC+
(5'-GGCTCATCGAAGAGCAAGCCTAAGGACGAACTTGATGTTGAAGC-3') and SRC
(5'-GTCCTTAGGCTTGCTCTTCGATGAGCCCATTGTCTATTGGCTTT-3') to create the
Myr and Myr-R50A proviruses. The Env deletion mutants were cloned
with a 2,536-bp fragment (PacI [position 4644] to BlpI [position 9193]) from the provirus
MN (deleted
from MroI [BspEI] [position 6957] to
NdeI [position 8970] provided by Martin Loechelt)
(2).
All 293T cell transfections were conducted with proviruses containing
the immediate-early promoter from the cytomegalovirus (CMV) in place of
the U5 region of the 5' long terminal repeat (LTR) sequence of pHSRV13,
such that expression of the viral RNA is initiated from the same
nucleotide as for the wild-type RNA transcribed from U3 (D. Baldwin and
M. Linial, unpublished data). Briefly, the CMV immediate-early promoter
was PCR amplified from pCR3.0 (Invitrogen) with oligonucleotide primers
containing EagI and XhoI sites (5' and 3',
respectively) to clone into a modified pHSRV13 subclone (sub1)
described previously (2) containing a linker with an
additional XhoI site between EagI and
XhoI (Baldwin and Linial, unpublished). The R50A and
Myr-R50A mutants were introduced into CMVsub1 with restriction sites
AvrII and PflMI.
Cells and transfections.
FAB indicator cells, BHK cells
containing an integrated copy of the
-galactosidase gene under the
control of the SFVcpz(hu) LTR (49), were maintained in
Dulbecco's modified Eagle's medium (DMEM) supplemented with 5% fetal
bovine serum. Human embryonic lung cells (HEL), thymocytes (CF3TH), and
293 T cells were maintained in Dulbecco's modified Eagle's medium
with 10% fetal bovine serum. FAB cell transient transfections were
conducted using the Lipofectamine reagent (Life Technologies, Inc.) as
previously described (2) with 5 µg of proviral DNA, as
well as the Fugene reagent (Roche Molecular Biochemicals) in which 10 µg of proviral DNA was added to 250 µl of DMEM containing 25 µl
of Fugene, mixed and incubated at room temperature for 15 min, added to
cells in 10 ml of medium, and rinsed after 24 h. 293 T cell
transient transfections were conducted using a modified calcium
phosphate method (6) in which 8 µg of proviral DNA plus
2 µg of LTR-GFP reporter plasmid were combined with 0.5 ml of 0.25 M
CaCl2, then added to 0.5 ml of 2× BES buffered solution
mixed and incubated at room temperature for 20 min, and added for 18 to
20 h to 10-cm-diameter dishes containing cells at approximately 75 to
85% confluency in 10 ml of medium.
Western blotting.
Proteins were analyzed by Western blotting
of cell lysates and viral supernatants with the anti-Gag polyclonal
antiserum as previously described (2), with the following
modifications. FAB and 293 T cells were scraped in phosphate-buffered
saline (PBS) 40 to 42 h posttransfection, pelleted, and rinsed
three times with PBS. Cell pellets were lysed in 1 ml of antibody
buffer (20 mM Tris [pH 7.5], 50 mM NaCl, 0.5% NP-40, 0.5% sodium
dodecyl sulfate [SDS], 0.5% deoxycholate, 0.5% aprotinin,
supplemented with 100 µg of phenylmethylsulfonyl fluoride per ml and
1 µg of leupeptin per ml), passed through a 23-gauge syringe to shear chromosomal DNA, cleared of cell debris by centrifugation in the microcentrifuge, mixed with SDS protein sample buffer, boiled, and
loaded on SDS-polyacrylamide gel electrophoresis (PAGE) minigels (10%
polyacrylamide). Culture supernatants were passed through 0.45-µm-pore-size syringe filters and pelleted through a 20% sucrose cushion (2 ml) at 24,000 rpm and 4°C for 2 h in a total volume of
17.5 ml (SW28 rotor; Beckman). Viral pellets were resuspended with
protein sample buffer and loaded onto SDS-PAGE minigels (10% polyacrylamide). After separation, proteins were transferred to Immobilon-P membranes (Millipore), blocked in 5% nonfat milk in PBS,
and incubated with anti-Gag antiserum at 1:2,000 overnight. The
membranes were washed three times in PBS containing 0.1% Tween 20 (PBS-T) and incubated with horseradish peroxidase-conjugated anti-rabbit immunoglobulin (Amersham) antibody at 1:7,500 dilution for
1 h. They were then washed four times for 20 min in PBS-T and
visualized by enhanced chemiluminescence (Amersham).
Linear-velocity sedimentation gradients.
Transiently
transfected 293 T cells were washed with PBS and lysed in NP-40 lysis
buffer (1% NP-40, 50 mM NaCl, 10 mM Tris-Cl [pH 7.4], 5 mM EDTA) for
30 min on ice. Lysates were cleared with an initial low-speed
centrifugation at 4,000 × g for 10 minutes followed by
centrifugation at 15,000 × g for 5 min in a
microcentrifuge, and the resulting supernatants were pelleted through
750 µl of 20% sucrose in TNE (20 mM Tris [pH 7.5], 150 mM NaCl, 1 mM EDTA) at 25,000 rpm for 2 h and 4°C in a total volume of 5 ml
(Ti55 rotor; Beckman). The pellets were resuspended in 300 µl of TNE, placed onto 5 ml of NP-40 lysis buffer containing sucrose step gradients consisting of 1.2 ml of 20%, 2 ml of 40%, and 1.5 ml of
66% sucrose, and ultracentrifuged at 30,000 rpm for 1 h (Ti55 rotor; Beckman) at 4°C, and eight 635-µl fractions were collected from the top, as well as the pellet fraction (resuspended in NP-40 lysis buffer) (26). Fractions were precipitated for 1 h at
20°C with trichloroacetic acid (TCA) (consisting of a final
concentration of 25%) and 10 µg of yeast tRNA, centrifuged at 16,000 × g for 20 min in a microcentrifuge, washed with 10% TCA
and then with 100% acetone, air dried, and resuspended in 1× protein
sample buffer. Fractions were subjected to SDS-PAGE (10%
polyacrylamide) and Western blotting. Extracellular virus was recovered
from culture supernatants by pelleting through 20% sucrose and
analyzed on these gradients after removal of viral envelopes by
treatment with 1% NP-40 in TNE.
Indirect immunofluorescence (IFA).
Transiently transfected
FAB cells on glass coverslips were rinsed with PBS and fixed for 5 min
at room temperature with 4% paraformaldehyde at 36 to 40 h
posttransfection. The cells were permeabilized with 1% Triton-X in PBS
for 5 min, washed with PBS, and blocked in 5% heat-inactivated bovine
serum albumin for at least 30 min at 4°C. The coverslips were then
rinsed and incubated with anti-Gag serum (1:2,000) for 1 h at
37°C, rinsed with PBS for 15 min three times, incubated with
anti-rabbit fluorescein isothiocyanate (FITC)-conjugated antibody
(1:1,000) for 45 min at 25°C, and rinsed with PBS as before. They
were then stained with 4',6-diamidino-2-phenylindole (DAPI; 0.2, µg/ml) for 5 min in double-distilled H2O washed in
double-distilled H2O, and mounted in Vectashield (Vector
Laboratories). Imaging was performed using a Nikon TE300 microscope and
Metamorph software.
 |
RESULTS |
Point mutation of the arginine at position 50 (R50) of FV Gag
inhibits particle assembly and blocks viral budding.
Analysis of
the Gag amino acid sequence of all FV isolates shows an absolute
conservation of the arginine at position 50 (R50) from the N terminus
(Fig. 1A). The sequence of SFVcpz(hu)
in the vicinity of this conserved R50 is reminiscent of the CTRS of the D-type retrovirus MPMV (Fig. 1B) (7, 38), including a
number of identical residues (7, 38), comprising a domain
of FV Gag [GXWGX3RX7L(Q/V)D]
(42). To determine whether R50 of SFVcpz(hu) is
involved in intracytoplasmic assembly, we made substitutions to alanine
(R50A) and tryptophan (R50W) (Fig. 1C). Proviral mutants under the
control of the CMV immediate-early promoter were transfected into 293T
cells along with the wild-type (wt) molecular clone of SFVcpz(hu),
HSRV. Intracellular Gag proteins and extracellular virus that was
purified from culture supernatants were then analyzed by Western
blotting. The cellular Gag expression levels (Fig. 2A) of R50A and R50W were comparable to
those of wt HSRV. Extracellular release of virus (Fig. 2B), however,
was completely abolished with these mutant proviruses compared to the
budding competent virus. wt HSRV cannot spread in this cell type and
therefore provides a proper control for a single-cycle infection. We
performed the same transient-transfection experiments with FAB cells,
which are permissive for replication and viral spread, to determine whether the block to assembly and viral release was cell type specific,
and we observed identical results (data not shown).

View larger version (26K):
[in this window]
[in a new window]
|
FIG. 1.
Schematic representation of FV Gag sequence alignments,
genomic structure map, and location of proviral mutants. (A) Sequence
alignment of the N-terminal portion of the Gag protein from all
characterized FV molecular clones including the amino acid position
number. *, absolute conservation; /, conservative change.
(B) Sequence alignment (Clustal W) of the N-terminal portion of
SFVcpz(hu) Gag with the CTRS domain from the D-type retrovirus
MPMV, with the absolutely conserved Arg residue highlighted in bold.
(C) Genomic structure of SFVcpz(hu) gag including the 5'
region of CMV-driven HSRV proviral constructs containing the CMV
immediate-early promoter in place of the 5' LTR for initiation of viral
transcription. The location of all proviral mutant sequences is shown
in relation to wt HSRV. The Myr mutant contains the 10-amino-acid
N-terminal Src myristylation signal (MGSSKSKPKD) in place of
the first 10 amino acids of Gag. R50A and R50W have alanine and
tryptophan substitutions, respectively, of the conserved arginine
residue at position 50. Env proviruses have a 2-kb deletion in
env (2).
|
|

View larger version (33K):
[in this window]
[in a new window]
|
FIG. 2.
R50A/W mutation blocks the release of virus from
FV-transfected cells. Western blot analysis of transiently transfected
293T cells expressing proteins from wt and mutant CMV-driven proviruses
is shown. (A) Cellular lysates prepared 40 h posttransfection from
cells transfected with HSRV or the conserved Arg substitution mutants
R50A and R50W, as well as a mock-transfected negative control. (B)
Extracellular virus isolated from the same culture supernatants by 20%
sucrose cushion sedimentation, including wt HSRV, the conserved Arg
substitution mutants R50A and R50W, and the mock-transfected negative
control. Viral proteins were visualized using the anti-Gag sera. MW,
molecular weight in thousands.
|
|
Next, we tested the hypothesis that the lack of particle budding
observed with the R50A/W mutants is caused by the inhibition
of
intracellular capsid assembly. We first used a standard
equilibrium
density centrifugation method to detect assembled
retroviral particles
in the cell. Transiently transfected FAB cell
lysates were placed
on gradients by previously described methods
(
1), and Gag protein
was found to band at a density of
approximately 1.14 g/ml for
both the wt and R50A mutant proviruses on
Western blots (data
not shown). This finding was both inconsistent with
our prediction
of FV intracellular assembly occurring via a CTRS-type
domain
and puzzling since we observed a complete lack of extracellular
virus produced from the R50A mutant provirus. However, previous
experiments performed in the laboratory using proviral mutants
lacking
gag (

Gag) indicated that viral polymerase proteins
exhibited
banding characteristics that are indistinguishable from
banding
seen with wt virus on Western blots of fractions collected from
identical density equilibrium gradients (Baldwin and Linial,
unpublished).
Thus, the equilibrium centrifugation does not appear to
distinguish
between unassembled viral protein complexes and assembled
viral
capsids under these conditions. Therefore, we used the
linear-velocity
sedimentation techniques that were previously used to
examine
the human immunodeficiency virus (HIV) capsid assembly pathway
(
26). We used a modified lysis procedure with 1% NP-40 in
an
attempt to discriminate bona fide intracellular capsids from
unassembled
Gag monomers and protein aggregates. Cell lysates were
centrifuged
through 20% sucrose, and the pelleted material was placed
on linear-velocity
sedimentation gradients made from 20 to 66% sucrose
containing
1% NP-40 and centrifuged under conditions found to band HIV
capsids
(approximately 750S) in the middle of the gradient (fraction 5)
(
26). We found that whereas cellular expression levels of
HSRV
and R50A mutant Gag were identical (Fig.
3A), the R50A mutant
gradient was devoid
of Gag protein compared with the wt gradient
containing Gag capsids in
fraction 6 (Fig.
3B). This indicated
that the initial 20% sucrose spin
separated actual capsids (HSRV)
from protein aggregates (R50A).

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 3.
R50A mutation inhibits capsid assembly. Western blot
analysis of transiently transfected 293T cells expressing proteins from
wt and mutant CMV-driven proviruses is shown. (A) Total-cell lysates.
(B) Cell lysates from HSRV and the R50A mutant. These lysates were
pelleted through 20% sucrose, resuspended in TNE, and layered onto 20, 40, and 66% sucrose linear velocity sedimentation gradients. Fractions
were collected from the top of the gradients (lane 1) and TCA
precipitated. Viral proteins were visualized using the anti-Gag sera.
The arrow indicates the location of HIV ~750S particles analyzed on
parallel gradients.
|
|
Plasma membrane targeting of R50A restores capsid assembly and
extracellular release of virus.
We next tested whether the R50A
mutant, lacking a putative intracellular signaling domain, could
synthesize particles if supplied with an alternate targeting signal.
There is precedent for this type of experiment, since studies with the
mouse intracisternal A-type particle retrovirus, which assembles and
buds capsids into the ER that remain within the ER lumen, have shown
that redirection of Gag to the PM by myristylation allows extracellular
release of virus (43). We substituted the Src targeting
signal, a 10-amino-acid N-terminal peptide previously reported to act
as a dominant plasma membrane-targeting domain dependent on
myristylation and the presence of 3 lysine residues, for the first 10 amino acids at the N terminus of the R50A mutant Gag protein to produce
the Myr-R50A provirus (Fig. 1B) (44, 45). CMV-driven
proviral mutants or HSRV were transiently transfected into 293 T cells,
and cellular lysates and viral supernatants were analyzed. We
first checked the ability of the myristylated form of the R50A
mutant (Myr-R50A) to form intracellular capsids by using the
intracellular assembly assay described above. Cellular lysates from
HSRV- or Myr-R50A-transfected cells (Fig.
4A) were pelleted through 20% sucrose,
placed on linear-velocity gradients, and fractionated. Remarkably,
these results indicated that the Myr-R50A mutant Gag was able to pellet
through 20% sucrose and was found to possess Gag sedimentation
characteristics indistinguishable from those of the wt on the
linear-velocity gradients (Fig. 4B).

View larger version (25K):
[in this window]
[in a new window]
|
FIG. 4.
Plasma membrane targeting of R50A mutant with the Src-
myristylation signal restores intracellular capsid assembly. Western
blot analysis of transiently transfected 293T cells expressing proteins
from wt and mutant CMV-driven proviruses is shown. (A) Total-cell
lysates. (B) Linear-velocity sedimentation gradient analysis of cell
lysates from HSRV (top) and Myr-R50A mutants (bottom). Viral proteins
were visualized using the anti-Gag sera.
|
|
Next, we determined whether myristylation of R50A Gag could restore
viral budding. Again, 293 T cells were transfected with
the proviral
constructs and Western blot analyses were performed
from whole-cell
lysates. The results show similar expression levels
of cellular Gag
(Fig.
5A) for HSRV, R50A, and Myr-R50A,
although
proteolytic processing of Gag was inhibited. Analysis of
purified
culture supernatants (Fig.
5B), however, revealed a
rescue of
viral release on addition of the PM-targeting
signal (Myr-R50A),
at levels comparable to those for HSRV, whereas the
R50A mutant
did not release virus. We consistently observed the absence
of
Gag cleavage with the extracellular Myr-R50A viruses. Identical
results were observed using FAB cells (data not shown). In addition,
extracellular virus produced from cells transfected with HSRV
or the
Myr-R50A mutant proviruses (Fig.
5C, cell lysate) was analyzed
on
linear-velocity sedimentation gradients after removal of the
viral
envelope with 1% NP-40. The results show that the Myr-R50A
mutant exhibited sedimentation characteristics identical to those
of wt HSRV, with Gag banding in fraction 6 (Fig.
5C). The infectivity
of the Myr-R50A was assessed using the FAB assay (
49), and
the
virus was found to be noninfectious, containing less than 1 infectious
unit (IU) per ml of culture supernatant, compared with
10
5 to 10
6 IU/ml for wt virus (data not shown).

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 5.
Plasma membrane targeting of R50A mutant restores viral
budding. Western blot analysis of transiently transfected 293T cells
expressing proteins from wt and mutant CMV-driven proviruses is
shown. (A) Cell lysates prepared 41 h posttransfection
including HSRV, the R50A mutant, and the myristylated R50A
mutant, Myr-R50A, as well as a mock-transfected negative control. (B)
Extracellular virus isolated from culture supernatants of the same cell
transfections by 20% sucrose cushion centrifugation. (C)
Linear-velocity sedimentation gradients of extracellular virus (treated
with 1% NP-40 to remove viral envelope) produced from cells
transfected with the HSRV (top) and Myr-R50A (bottom) proviruses
(whole-cell lysates shown at left). Viral proteins were visualized
using anti-Gag sera. MW, molecular weight in thousands.
|
|
Subcellular localization of mutant Gag proteins and assembled
capsid structures.
Subcellular localization of the mutant viral
proteins was analyzed by indirect immunofluorescence (IFA) of
transiently transfected FAB cells using the anti-Gag serum. Expected
distinctive nuclear fluorescence was seen in cells transfected with
HSRV (Fig. 6B), as well as the R50A
mutant (Fig. 6C) (41). Addition of the Src membrane-binding domain to wt and R50A mutant Gag significantly altered
protein localization. Cell nuclei appeared dark with a corresponding
punctate staining of cytoplasmic regions including PM sites (Fig. 6D
and E). Comparison of the Myr mutants with a mutant lacking the NLS in
GR box II,
NLS (50) (Fig. 6F), revealed that whereas
nuclei were not stained in either case, the Myr-tagged proteins
appeared to accumulate in brightly staining regions within the
cytoplasm and at the PM, as opposed to the diffuse cytoplasmic staining
seen in cells transfected with the
NLS mutant. These staining
patterns are reminiscent of HIV Gag localization with and without
N-terminal myristylation, respectively (31).

View larger version (93K):
[in this window]
[in a new window]
|
FIG. 6.
Subcellular Gag localization using IFA.
Transiently transfected FAB cells (phase-contrast images [left
panel]) were fixed 36 to 40 h posttransfection,
incubated with anti-Gag sera, and visualized with FITC (center panel).
Nuclei are stained with DAPI (right panel). The proviruses are
mock (A) HSRV (B), the R50A mutant (C), Myr (D), and Myr-R50A
(E), as well as the control mutant lacking the NLS in GR box II, NLS
(F) (48).
|
|
Redirection of Gag to the plasma membrane allows FV particle
budding in the absence of Env.
We next examined whether the
intracellular assembly mutant virus containing the PM-targeting signal,
Myr-R50A, required Env glycoprotein synthesis for extracellular
release. Our previous finding that particle budding is dependent on the
presence of Env suggests that FV capsids do not possess an inherent
membrane-targeting signal and that specific Gag-Env interactions are
required for capsids to be released from the cell. We hypothesized that
if Gag was given a specific mechanism for localization, such as the Src
plasma membrane-targeting signal, the Env requirement could be bypassed
and capsids would bud from the PM in the absence of Env expression. We
deleted most of the env gene from each provirus to create
mutants (
Env) that do not express Env but do express all other
proteins at wt levels and conducted transfection experiments as before
(2). Western blot analysis of cellular lysates from 293 T
cells transiently transfected with the mutant proviral clones showed
comparable levels of intracellular Gag (Fig.
7A). Analysis of extracellular virus
purified from these culture supernatants (Fig. 7B), however, showed
that in the absence of Env expression, the Myr/
Env (lane 8) and
Myr-R50A/
Env (lane 9) mutants released virus at levels at or
surpassing those of budding-competent noninfectious control viruses
D936I (integrase mutant, lane 2), and HSRV-D/A (protease active site
mutant, lane 3). In contrast, HSRV/
Env (lane 7) was completely
inhibited in particle release, similar to the R50A mutant (lane 4) and
mock transfected cells (lane 1).

View larger version (35K):
[in this window]
[in a new window]
|
FIG. 7.
Myr-R50A mutant virus budding in the absence of Env.
Western blot analysis of CMV-driven mutant proviruses transfected into
293 T cells is shown (A) Cell lysates prepared 41 h
posttransfection, including the integrase mutant, D936I (lane 2), and
the protease active-site mutant, HSRV-D/A (lane 3), R50A (lane 4), Myr
(lane 5), Myr-R50A (lane 6), the HSRV envelope deletion, HSRV/ Env
(lane 7), Myr/ Env (lane 8), and Myr-R50A/ Env (lane 9), as well as
mock-transfected cells (lane 1). (B) Extracellular virus purified from
the same culture supernatants by 20% sucrose cushion centrifugation,
with the same lane designations. Viral proteins were visualized using
anti-Gag sera.
|
|
 |
DISCUSSION |
In this study, we have shown that a single substitution of an
absolutely conserved residue in the N-terminal region of FV Gag
severely inhibits intracellular capsid assembly and ablates viral
particle release. This residue (R50) is situated in a region of high
conservation among all characterized FVs and has moderate homology to
the recently defined CTRS signal from the D-type retrovirus MPMV
(7). Nuclear magnetic resonance analysis of the MA domain of MPMV Gag suggests that the 18-amino-acid CTRS region exists on an
exposed loop of the protein, not found in the matrix domain of Gag from
C-type viruses (11, 12). The CTRS is proposed to target
and retain Gag molecules at a specific site within the cell, allowing
for localized increases in protein concentrations such that Gag-Gag
interactions and assembly may proceed (7). It is also
likely that a cellular factor(s) is involved in the targeting process,
a hypothesis supported by the recent report of the discovery of an
insect cell line defective in the transport of assembled capsids to the
PM (32). We propose that FV assembly occurs free of
membranes in a fashion similar to the B- and D-type retroviruses and
that capsid formation is mediated by a signal akin to the CTRS domain.
Targeting domains for all characterized retroviral Gag proteins reside
at the amino-terminal MA domain (24). There is no obvious
membrane-targeting signal on FV Gag, and, correspondingly, we found
that a disruption of the cytoplasmic assembly signal blocked capsid
formation altogether. If a PM targeting signal was provided, however,
in the form of the Src myristylation signal, as in Myr or Myr-R50A,
capsid assembly proceeded and particle release was restored to wt
levels. A switch to C-type assembly at the PM was not detected with
these mutants when transiently transfected cells were analyzed by
electron microscopy, but this mechanism of capsid formation cannot be
ruled out. Indeed, we found that the total amounts of intracellular
Myr-R50A mutant Gag were always significantly reduced compared to HSRV
(Fig. 5A) in cells transfected with similar levels of provirus as
detected by cotransfection of an LTR-GFP plasmid. Extracellular
Myr-R50A virus, however, was found to be present at wt levels (Fig.
5B), indicating that PM targeting of Gag may be increasing the
efficiency of capsid assembly and budding.
Of considerable interest is the fact that myristylated Gag proteins
created capsids that budded from cells in the absence of Env
expression. FV capsids are capable of budding from the PM rather than
the ER. SFVcpz(hu) mutant viruses, which lack the Env ER retention
signal, will bud at wt levels from the PM, where Env is localized
(17, 18). Interestingly, the equine and bovine FV possess
sequences homologous to the intracellular assembly domain (Fig. 1A) but
lack the ER retention signal on the Env protein and, correspondingly,
bud virus solely from the PM (21, 42). Recently, it has
been reported that the N terminus of the leader peptide of
SFVcpz(hu) Env, termed the budding domain, is required for
efficient particle release (25). We propose that
intracellular budding of FV capsids is a process normally driven by a
Gag-Env interaction but that if capsids are given an alternate
localization signal, such as the N-terminal Src membrane-targeting
signal on Gag, budding may occur from the PM in the absence of Env.
Also of interest is the observation that extracellular virus produced
from the Myr-R50A mutant exhibited reduced Gag cleavage and was
noninfectious. While many FV mutations cause slight alterations in
intracellular Gag cleavage, virus released from cells containing the
Myr-R50A Gag mutant provirus appeared to be devoid of any proteolytic
processing (Fig. 5B; compare lanes 6 and 8; Fig. 7B, compare lanes 2 and 6), whereas the provirus with only the Src-targeting signal (Myr)
produced virus with an intermediate cleavage phenotype (Fig. 7B,
compare lanes 2, 5, and 6). Several possibilities could account for
this deficiency in Gag cleavage. Addition of the Src signal to Gag may
alter the proper folding and conformation of the protein such that
processing is prevented. Also, it is conceivable that these mutant
viral particles lack a cellular factor required for protease activation
or that these mutant virus particles have reduced levels of Pol. If
capsid formation is highly site specific, perhaps a specific mechanism
exists to target Pol into assembling particles; thus, any perturbation
of the site of assembly will affect Pol incorporation. Alternatively,
these particles may be devoid of viral nucleic acid, which may also
influence the levels of Pol in virus. A recent study analyzing the
region upstream of the primer-binding site of SFVcpz(hu) indicates
that deletion of a 29-nucleotide domain in the U5 region of the 5' LTR,
while having no effect on packaging of nucleic acid, inhibits Gag
cleavage in extracellular virus (20). Perhaps assembly of
RNA and Pol into capsids is a highly coordinated event occurring at a
discrete location and subtle mutations in Gag have a substantial impact on this process.
The block to infection by the Myr-R50A virus could be due to the lack
of cleavage, Pol and/or genome packaging, or failure to incorporate
Env. Previous experiments by others have shown that C-terminal Gag
cleavage is essential for infectivity (13, 51). However,
Myr-R50A viruses, which appear to bud from the plasma membrane, are
also likely to be missing Env. Lack of Env would block the Myr-R50A
viruses from entering new cells. The presence of Pol, Env, and RNA in
these viruses is currently under investigation. Our data indicate that
the site of assembly of FV capsids is critical for the formation of an
infectious viral particle. Although FV capsids have the inherent
ability to assemble at different sites within the cell including the
PM, assembly at the CTRS-mediated intracellular site appears to be
essential for proper incorporation of all viral components.
 |
ACKNOWLEDGMENTS |
S.W.E. was supported by Viral Oncology Training Grant T32 0229 from the National Cancer Institute. This investigation was also
supported by grant CA18282 from the National Cancer Institute to M.L.L.
We thank Jaisri Lingappa (University of Washington, Pathobiology) for
assistance with linear-velocity sedimentation gradients as well as
invaluable suggestions and discussion, and we thank Michael Emerman
(FHCRC) for critical review of the manuscript.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Division of
Basic Sciences, Fred Hutchinson Cancer Research Center, A3-015, 1100 Fairview Ave. N., Seattle, WA 98109-1024. Phone: (206) 667-4442. Fax:
(206) 667-5939. E-mail: mlinial{at}fhcrc.org.
 |
REFERENCES |
| 1.
|
Baldwin, D. N., and M. L. Linial.
1999.
Proteolytic activity, the carboxy terminus of Gag, and the primer binding site are not required for Pol incorporation into foamy virus particles.
J. Virol.
73:6387-6393[Abstract/Free Full Text].
|
| 2.
|
Baldwin, D. N., and M. L. Linial.
1998.
The roles of Pol and Env in the assembly pathway of human foamy virus.
J. Virol.
72:3658-3665[Abstract/Free Full Text].
|
| 3.
|
Boulanger, P., and I. Jones.
1996.
Use of heterologous expression systems to study retroviral morphogenesis.
Curr. Top. Microbiol. Immunol.
214:237-260[Medline].
|
| 4.
|
Bowzard, J. B.,
R. P. Bennett,
N. K. Krishna,
S. M. Ernst,
A. Rein, and J. W. Wills.
1998.
Importance of basic residues in the nucleocapsid sequence for retrovirus Gag assembly and complementation rescue.
J. Virol.
72:9034-9044[Abstract/Free Full Text].
|
| 5.
|
Bruss, V., and D. Ganem.
1991.
The role of envelope proteins in hepatitis B virus assembly.
Proc. Natl. Acad. Sci. USA
88:1059-1063[Abstract/Free Full Text].
|
| 6.
|
Chen, C., and H. Okayama.
1987.
High-efficiency transformation of mammalian cells by plasmid DNA.
Mol. Cell. Biol.
7:2745-2752[Abstract/Free Full Text].
|
| 7.
|
Choi, G.,
S. Park,
B. Choi,
S. Hong,
J. Lee,
E. Hunter, and S. S. Rhee.
1999.
Identification of a cytoplasmic targeting/retention signal in a retroviral Gag polyprotein.
J. Virol.
73:5431-5437[Abstract/Free Full Text].
|
| 8.
|
Chopra, H. C.,
J. J. Hooks,
M. J. Walling, and C. J. Gibbs, Jr.
1972.
Morphology of simian foamy viruses, with particular reference to virus isolated from spontaneous tumor of a rhesus monkey.
J. Natl. Cancer Inst.
48:451-463.
|
| 9.
|
Clarke, J. K., and J. T. Attridge.
1968.
The morphology of simian foamy agents.
J. Gen. Virol.
3:185-190[Abstract/Free Full Text].
|
| 10.
|
Clarke, J. K.,
F. W. Gay, and J. J. Attridge.
1969.
Replication of simian foamy virus in monkey kidney cells.
J. Virol.
3:358-362[Abstract/Free Full Text].
|
| 11.
|
Conte, M. R.,
M. Klikova,
E. Hunter,
T. Rumi, and S. Matthews.
1997.
The three-dimensional solution structure of the matrix protein from the type D retrovirus, the Mason-Pfizer monkey virus, and implications for the morphology of retroviral assembly.
EMBO J.
16:5819-5826[CrossRef][Medline].
|
| 12.
|
Conte, M. R., and S. Matthews.
1998.
Retroviral matrix proteins: a structural perspective.
Virology
246:191-198[CrossRef][Medline].
|
| 13.
|
Enssle, J.,
N. Fischer,
A. Moebes,
B. Mauer,
U. Smola, and A. Rethwilm.
1997.
Carboxy-terminal cleavage of the human foamy virus Gag precursor molecule is an essential step in the viral life cycle.
J. Virol.
71:7312-7317[Abstract].
|
| 14.
|
Enssle, J.,
I. Jordan,
B. Mauer, and A. Rethwilm.
1996.
Foamy virus reverse transcriptase is expressed independently from the Gag protein.
Proc. Natl. Acad. Sci. USA
93:4137-4141[Abstract/Free Full Text].
|
| 15.
|
Fischer, N.,
M. Heinkelein,
D. Lindemann,
J. Enssle,
C. Baum,
E. Werder,
H. Zentgraf,
J. G. Muller, and A. Rethwilm.
1998.
Foamy virus particle formation.
J. Virol.
72:1610-1615[Abstract/Free Full Text].
|
| 16.
|
Giron, M. L.,
S. Colas,
J. Wybier,
F. Rozain, and R. Emanoil-Ravier.
1997.
Expression and maturation of human foamy virus Gag precursor polypeptides.
J. Virol.
71:1635-1639[Abstract].
|
| 17.
|
Goepfert, P. A.,
K. Shaw,
G. Wang,
A. Bansal,
B. H. Edwards, and M. J. Mulligan.
1999.
An endoplasmic reticulum retrieval signal partitions human foamy virus maturation to intracytoplasmic membranes.
J. Virol.
73:7210-7217[Abstract/Free Full Text].
|
| 18.
|
Goepfert, P. A.,
K. L. Shaw,
G. D. Ritter, Jr., and M. J. Mulligan.
1997.
A sorting motif localizes the foamy virus glycoprotein to the endoplasmic reticulum.
J. Virol.
71:778-784[Abstract].
|
| 19.
|
Goepfert, P. A.,
G. Wang, and M. J. Mulligan.
1995.
Identification of an ER retrieval signal in a retroviral glycoprotein.
Cell
82:543-544[CrossRef][Medline].
|
| 20.
|
Heinkelein, M.,
J. Thurow,
M. Dressler,
H. Imrich,
D. Neumann-Haefelin,
M. O. McClure, and A. Rethwilm.
2000.
Complex effects of deletions in the 5' untranslated region of primate foamy virus on viral gene expression and RNA packaging.
J. Virol.
74:3141-3148[Abstract/Free Full Text].
|
| 21.
|
Holzschu, D. L.,
M. A. Delaney,
R. W. Renshaw, and J. W. Casey.
1998.
The nucleotide sequence and spliced pol mRNA levels of the nonprimate spumavirus bovine foamy virus.
J. Virol.
72:2177-2182[Abstract/Free Full Text].
|
| 22.
|
Hooks, J. J., and C. J. Gibbs, Jr.
1975.
The foamy viruses.
Bacteriol. Rev.
39:169-185[Free Full Text].
|
| 23.
|
Keller, A.,
K. M. Partin,
M. Lochelt,
H. Bannert,
R. M. Flugel, and B. R. Cullen.
1991.
Characterization of the transcriptional trans activator of human foamy retrovirus.
J. Virol.
65:2589-2594[Abstract/Free Full Text].
|
| 24.
|
Krausslich, H. G., and R. Welker.
1996.
Intracellular transport of retroviral capsid components.
Curr. Top. Microbiol. Immunol.
214:25-63[Medline].
|
| 25.
|
Lindemann, D.,
T. Pietschmann,
M. Picard-Maureau,
A. Berg,
M. Heinkelein,
P. K. J. Thurow,
H. Zentgraf, and A. Rethwilm.
2001.
A particle-associated glycoprotein signal peptide essential for virus maturation and infectivity.
J. Virol.
75:5762-5771[Abstract/Free Full Text].
|
| 26.
|
Lingappa, J. R.,
R. L. Hill,
M. L. Wong, and R. S. Hegde.
1997.
A multistep, ATP-dependent pathway for assembly of human immunodeficiency virus capsids in a cell-free system.
J. Cell Biol.
136:567-581[Abstract/Free Full Text].
|
| 27.
|
Linial, M. L.
1999.
Foamy viruses are unconventional retroviruses.
J. Virol.
73:1747-1755[Free Full Text].
|
| 28.
|
Lochelt, M., and R. M. Flugel.
1996.
The human foamy virus pol gene is expressed as a Pro-Pol polyprotein and not as a Gag-Pol fusion protein.
J. Virol.
70:1033-1040[Abstract].
|
| 29.
|
Lochelt, M.,
W. Muranyi, and R. M. Flugel.
1993.
Human foamy virus genome possesses an internal, Bel-1-dependent and functional promoter.
Proc. Natl. Acad. Sci. USA
90:7317-7321[Abstract/Free Full Text].
|
| 30.
|
Lochelt, M.,
H. Zentgraf, and R. M. Flugel.
1991.
Construction of an infectious DNA clone of the full-length human spumaretrovirus genome and mutagenesis of the bel 1 gene.
Virology
184:43-54[CrossRef][Medline].
|
| 31.
|
Ono, A.,
D. Demirov, and E. O. Freed.
2000.
Relationship between human immunodeficiency virus type 1 Gag multimerization and membrane binding.
J. Virol.
74:5142-5150[Abstract/Free Full Text].
|
| 32.
|
Parker, S. D., and E. Hunter.
2000.
A cell-line-specific defect in the intracellular transport and release of assembled retroviral capsids.
J. Virol.
74:784-795[Abstract/Free Full Text].
|
| 33.
|
Pellman, D.,
E. A. Garber,
F. R. Cross, and H. Hanafusa.
1985.
An N-terminal peptide from p60src can direct myristylation and plasma membrane localization when fused to heterologous proteins.
Nature
314:374-377[CrossRef][Medline].
|
| 34.
|
Pfrepper, K. I.,
M. Lochelt,
H. R. Rackwitz,
M. Schnolzer,
H. Heid, and R. M. Flugel.
1999.
Molecular characterization of proteolytic processing of the Gag proteins of human spumavirus.
J. Virol.
73:7907-7911[Abstract/Free Full Text].
|
| 35.
|
Pfrepper, K. I.,
M. Lochelt,
M. Schnolzer, and R. M. Flugel.
1997.
Expression and molecular characterization of an enzymatically active recombinant human spumaretrovirus protease.
Biochem. Biophys. Res. Commun.
237:548-553[CrossRef][Medline].
|
| 36.
|
Rethwilm, A.,
O. Erlwein,
G. Baunach,
B. Maurer, and V. ter Meulen.
1991.
The transcriptional transactivator of human foamy virus maps to the bel 1 genomic region.
Proc. Natl. Acad. Sci. USA
88:941-945[Abstract/Free Full Text].
|
| 37.
|
Rhee, S. S., and E. Hunter.
1987.
Myristylation is required for intracellular transport but not for assembly of D-type retrovirus capsids.
J. Virol.
61:1045-1053[Abstract/Free Full Text].
|
| 38.
|
Rhee, S. S., and E. Hunter.
1990.
A single amino acid substitution within the matrix protein of a type D retrovirus converts its morphogenesis to that of a type C retrovirus.
Cell
63:77-86[CrossRef][Medline].
|
| 39.
|
Saib, A.,
F. Puvion-Dutilleul,
M. Schmid,
J. Peries, and H. de The.
1997.
Nuclear targeting of incoming human foamy virus Gag proteins involves a centriolar step.
J. Virol.
71:1155-1161[Abstract].
|
| 40.
|
Sakalian, M., and E. Hunter.
1999.
Separate assembly and transport domains within the Gag precursor of Mason-Pfizer monkey virus.
J. Virol.
73:8073-8082[Abstract/Free Full Text].
|
| 41.
|
Schliephake, A. W., and A. Rethwilm.
1994.
Nuclear localization of foamy virus Gag precursor protein.
J. Virol.
68:4946-4954[Abstract/Free Full Text].
|
| 42.
|
Tobaly-Tapiero, J.,
P. Bittoun,
M. Neves,
M. C. Guillemin,
C. H. Lecellier,
F. Puvion-Dutilleul,
B. Gicquel,
S. Zientara,
M. L. Giron,
H. de The, and A. Saib.
2000.
Isolation and characterization of an equine foamy virus.
J. Virol.
74:4064-4073[Abstract/Free Full Text].
|
| 43.
|
Welker, R.,
A. Janetzko, and H. G. Krausslich.
1997.
Plasma membrane targeting of chimeric intracisternal A-type particle polyproteins leads to particle release and specific activation of the viral proteinase.
J. Virol.
71:5209-5217[Abstract].
|
| 43a.
|
Wills, J. W., and R. C. Craven.
1991.
Form, function, and use of retroviral Gag proteins
AIDS
5:639-654[Medline].
|
| 44.
|
Wills, J. W.,
R. C. Craven, and J. A. Achacoso.
1989.
Creation and expression of myristylated forms of Rous sarcoma virus gag protein in mammalian cells.
J. Virol.
63:4331-4343[Abstract/Free Full Text].
|
| 45.
|
Wills, J. W.,
R. C. Craven,
R. A. Weldon, Jr.,
T. D. Nelle, and C. R. Erdie.
1991.
Suppression of retroviral MA deletions by the amino-terminal membrane-binding domain of p60src.
J. Virol.
65:3804-3812[Abstract/Free Full Text].
|
| 46.
|
Winkler, I.,
J. Bodem,
L. Haas,
M. Zemba,
H. Delius,
R. Flower,
R. M. Flugel, and M. Lochelt.
1997.
Characterization of the genome of feline foamy virus and its proteins shows distinct features different from those of primate spumaviruses.
J. Virol.
71:6727-6741[Abstract].
|
| 47.
|
Yu, S. F.,
D. N. Baldwin,
S. R. Gwynn,
S. Yendapalli, and M. L. Linial.
1996.
Human foamy virus replication: a pathway distinct from that of retroviruses and hepadnaviruses.
Science
271:1579-1582[Abstract].
|
| 48.
|
Yu, S. F.,
K. Edelmann,
R. K. Strong,
A. Moebes,
A. Rethwilm, and M. L. Linial.
1996.
The carboxyl terminus of the human foamy virus Gag protein contains separable nucleic acid binding and nuclear transport domains.
J. Virol.
70:8255-8262[Abstract].
|
| 49.
|
Yu, S. F., and M. L. Linial.
1993.
Analysis of the role of the bel and bet open reading frames of human foamy virus by using a new quantitative assay.
J. Virol.
67:6618-6624[Abstract/Free Full Text].
|
| 50.
|
Yu, S. F.,
M. D. Sullivan, and M. L. Linial.
1999.
Evidence that the human foamy virus genome is DNA.
J. Virol.
73:1565-1572[Abstract/Free Full Text].
|
| 51.
|
Zemba, M.,
T. Wilk,
T. Rutten,
A. Wagner,
R. M. Flugel, and M. Lochelt.
1998.
The carboxy-terminal p3Gag domain of the human foamy virus Gag precursor is required for efficient virus infectivity.
Virology
247:7-13[CrossRef][Medline].
|
Journal of Virology, August 2001, p. 6857-6864, Vol. 75, No. 15
0022-538X/01/$04.00+0 DOI: 10.1128/JVI.75.15.6857-6864.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Jouvenet, N., Neil, S. J. D., Zhadina, M., Zang, T., Kratovac, Z., Lee, Y., McNatt, M., Hatziioannou, T., Bieniasz, P. D.
(2009). Broad-Spectrum Inhibition of Retroviral and Filoviral Particle Release by Tetherin. J. Virol.
83: 1837-1844
[Abstract]
[Full Text]
-
Lee, E.-G., Linial, M. L.
(2008). The C Terminus of Foamy Retrovirus Gag Contains Determinants for Encapsidation of Pol Protein into Virions. J. Virol.
82: 10803-10810
[Abstract]
[Full Text]
-
Life, R. B., Lee, E.-G., Eastman, S. W., Linial, M. L.
(2008). Mutations in the Amino Terminus of Foamy Virus Gag Disrupt Morphology and Infectivity but Do Not Target Assembly. J. Virol.
82: 6109-6119
[Abstract]
[Full Text]
-
Zhadina, M., McClure, M. O., Johnson, M. C., Bieniasz, P. D.
(2007). Ubiquitin-dependent virus particle budding without viral protein ubiquitination. Proc. Natl. Acad. Sci. USA
104: 20031-20036
[Abstract]
[Full Text]
-
Mannigel, I., Stange, A., Zentgraf, H., Lindemann, D.
(2007). Correct Capsid Assembly Mediated by a Conserved YXXLGL Motif in Prototype Foamy Virus Gag Is Essential for Infectivity and Reverse Transcription of the Viral Genome. J. Virol.
81: 3317-3326
[Abstract]
[Full Text]
-
Stanke, N., Stange, A., Luftenegger, D., Zentgraf, H., Lindemann, D.
(2005). Ubiquitination of the Prototype Foamy Virus Envelope Glycoprotein Leader Peptide Regulates Subviral Particle Release. J. Virol.
79: 15074-15083
[Abstract]
[Full Text]
-
Cartellieri, M., Herchenroder, O., Rudolph, W., Heinkelein, M., Lindemann, D., Zentgraf, H., Rethwilm, A.
(2005). N-Terminal Gag Domain Required for Foamy Virus Particle Assembly and Export. J. Virol.
79: 12464-12476
[Abstract]
[Full Text]
-
Patton, G. S., Morris, S. A., Chung, W., Bieniasz, P. D., McClure, M. O.
(2005). Identification of Domains in Gag Important for Prototypic Foamy Virus Egress. J. Virol.
79: 6392-6399
[Abstract]
[Full Text]
-
Stange, A., Mannigel, I., Peters, K., Heinkelein, M., Stanke, N., Cartellieri, M., Gottlinger, H., Rethwilm, A., Zentgraf, H., Lindemann, D.
(2005). Characterization of Prototype Foamy Virus Gag Late Assembly Domain Motifs and Their Role in Particle Egress and Infectivity. J. Virol.
79: 5466-5476
[Abstract]
[Full Text]
-
Petit, C., Giron, M.-L., Tobaly-Tapiero, J., Bittoun, P., Real, E., Jacob, Y., Tordo, N., de The, H., Saib, A.
(2003). Targeting of incoming retroviral Gag to the centrosome involves a direct interaction with the dynein light chain 8. J. Cell Sci.
116: 3433-3442
[Abstract]
[Full Text]
-
Verschoor, E. J., Langenhuijzen, S., van den Engel, S., Niphuis, H., Warren, K. S., Heeney, J. L.
(2003). Structural and Evolutionary Analysis of an Orangutan Foamy Virus. J. Virol.
77: 8584-8587
[Abstract]
[Full Text]
-
Delelis, O., Saib, A., Sonigo, P.
(2003). Biphasic DNA Synthesis in Spumaviruses. J. Virol.
77: 8141-8146
[Abstract]
[Full Text]
-
Shaw, K. L., Lindemann, D., Mulligan, M. J., Goepfert, P. A.
(2003). Foamy Virus Envelope Glycoprotein Is Sufficient for Particle Budding and Release. J. Virol.
77: 2338-2348
[Abstract]
[Full Text]
-
Scheifele, L. Z., Rhoads, J. D., Parent, L. J.
(2002). Specificity of Plasma Membrane Targeting by the Rous Sarcoma Virus Gag Protein. J. Virol.
77: 470-480
[Abstract]
[Full Text]
-
Lecellier, C.-H., Neves, M., Giron, M.-L., Tobaly-Tapiero, J., Saib, A.
(2002). Further Characterization of Equine Foamy Virus Reveals Unusual Features among the Foamy Viruses. J. Virol.
76: 7220-7227
[Abstract]
[Full Text]